In advanced refractory urothelial tract and bladder cancers, where FGFR3 mutations are frequent2, the reversible FGFR1–FGFR4 inhibitor erdafitinib is approved for tumors harboring FGFR2 or FGFR3 point mutations or fusions6. Here, FGFR3 is linked to urinary bladder cancer.